Released Mar 17, 2025, after the close
10-Q filed Mar 17, 2025, 45 days after period end · 0001654954-25-002888
Q1 2025 · 10-Q
Revenue$2.47M$2.47M +3.8% vs Q1 2024+5.9% vs Q4 2024
Net Income$8.54K$8.54K N/M vs Q1 2024−47.0% vs Q4 2024
EPS Diluted$0.00$0.00 N/M vs Q1 2024no prior Q4 2024 on file
Gross Profit$768,109+43.4%
Operating Income-$92,191N/M
Operating Cash Flow-$429,486N/M
Free Cash Flowderived-$429,486N/M
Margins · derived
Gross margin31.1%+8.6 pt vs Q1 2024
Operating margin-3.7%+14.7 pt vs Q1 2024
Net margin0.3%+11.7 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $2.47M | $2.38M | $4.24M | $5.02M |
| Net Income | $8.54K | -$270.72K | $426.43K | $305.24K |
| EPS Diluted | $0.00 | -$0.01 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR